Welcome : Guest

EPIGENETICS - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Epigenetics in US$ Million by the following Application Areas: Drug Discovery, Diagnostics, and Others. Annual estimates and forecasts are provided for the period 2006 through 2015. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 39 companies including many key and niche players such as -

Celgene Corporation
CellCentric Ltd.
CellCentric Ltd.
Epigentek Group, Inc.
Genpathway, Inc.
Merck & Co., Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-6259
Price: $4500
Companies: 39
Pages: 339
Date: February 2010
Market Data Tables: 93
 



TABLE OF CONTENTS


  EPIGENETICS (Complete Report) Pages : 339   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Epigenetics: An Introduction.....II-1
Cancer: The Key Focus Area for Epigenetics.....II-1
Histone Changes as Biomarkers: An Emerging Field.....II-1
1$100
   Future of Epigenetics.....II-21$100
   Scope of Epigenetics.....II-3
Oncology.....II-3
Psychiatry.....II-3
1$100
   Outlook of Epigenetic Treatments.....II-4
Current and Future Analysis.....II-4
Market Segmentation.....II-4
Therapeutics.....II-4
1$100
   Diagnostics.....II-5
Research Tools.....II-5
Epigenetics Stretching to hESC Research.....II-5
Epigenetics: Transforming from Special Niche to Widespread Collection of Tools.....II-5
1$100
   Pros and Cons of First Generation Epigenetics Drugs.....II-6
Advances in Epigenetics Technologies, Therapeutics and Diagnostics.....II-6
1$100
   Outlook for Product Positioning and Innovation.....II-7
Epigenetic Community Initiatives.....II-7
Patent Law in Japan.....II-7
2$125
   Epigenomics Pioneers the Epigenetics Diagnostics.....II-9
Merck Leads HDAC Inhibitors Market.....II-9
Huge Potential for Novel Therapies.....II-9
Combination Therapy.....II-9
1$100
   Novel Technologies.....II-101$100
   Epigenetics - Definition.....II-11
Categories of Signals in Epigenetics.....II-11
Introduction.....II-11
1$100
   Etymology and Meaning.....II-12
Epigenetics - Molecular Base.....II-12
1$100
   Mechanisms.....II-13
Chromatin Remodeling and DNA Methylation.....II-13
2$125
   RNA Transcripts and Programmed Proteins.....II-15
Prions.....II-15
1$100
   Structural Inheritance Systems.....II-16
Functions and Outcomes.....II-16
Development.....II-16
Medicine.....II-16
Evolution.....II-16
1$100
   Epigenetics in Microorganisms.....II-171$100
   Epigentek Group Launches New Measures for DNA Methylation Shifts.....II-18
QIAGEN Introduces EpiTect® HRM™ PCR Kit.....II-18
Enzo Biochem Rolls Out Wide-Ranging Epigenetics Tools.....II-18
1$100
   Applied Biosystems Unveils Novel Small RNA Expression Analysis Solution.....II-19
Sigma-Aldrich Launches Imprint™ Methylated DNA Quantification Kit.....II-19
1$100
   Sigma-Aldrich Unveils ChIP Kit for Epigenetic Research.....II-20
Pyrosequencing Introduces New PyroMark™ Q24.....II-20
Qiagen Expands Epitect Portfolio.....II-20
1$100
   Applied Biosystems Introduces New SOLiD™ 3 System.....II-211$100
   Merck Merges with Schering-Plough.....II-22
Celldex Therapeutics Acquires CuraGen.....II-22
NCCN Upgrades Vidaza to Category 1.....II-22
PrognosDx Health Obtains UCLA Epigenetics Technology Rights.....II-22
1$100
   PROGEN Posts Positive Results from Preclinical Epigenetics Product.....II-23
Pharmacyclics Announces Positive Scientific Results from PCI-24781 Clinical Trial
  Targeting HDAC.....II-23
CellCentric Signs Agreement with Takeda.....II-23
1$100
   Orion Genomics and Novartis Ink Multi-Year Collaboration and License Agreement.....II-24
SuperGen Collaborates with GlaxoSmithKline.....II-24
QIAGEN to Acquire SABiosciences.....II-24
1$100
   QIAGEN Takes Over DxS.....II-25
CellCentric Expands Number of Researchers.....II-25
Roche NimbleGen Enters into Collaboration with Sigma-Aldrich.....II-25
Quest Diagnostics Gains biomarker license from Epigenomics.....II-25
1$100
   Babraham Institute Launches New Epigenomics Sequencing Facility.....II-26
Active Motif Enters into Licensing Agreement with City of Hope.....II-26
NIH to Grant US$62 Million for Epigenetic Research.....II-26
1$100
   Rush University Medical Center Obtains US$5.5 Million Grant from NIH.....II-27
Celgene Takes Over Pharmion.....II-27
Eisai Takes Over MGI PHARMA.....II-27
Affymetrix Acquires Panomics.....II-27
1$100
   QIAGEN Takes Over Biotage’s Biosystems.....II-28
Millipore Corporation and Agilent Technologies Collaborate.....II-28
Invitrogen Signs License Agreement with Genisphere.....II-28
1$100
   Invitrogen and IMBcom Proprietary Ink Licensing Agreement.....II-29
OncoMethylome Sciences and QIAGEN Sign Licensing Agreement.....II-29
Pharmacyclics Characterizes Highly Selective HDAC Inhibitor.....II-29
Celgene’s Vidaza Gains Approval for MDS and AML in Europe.....II-29
1$100
   Medistem Enters into Epigenetics Collaboration.....II-30
Orion Geomics Obtains License for IGF2 Gene from Johns Hopkins.....II-30
Progen Pharmaceuticals Acquires CellGate.....II-30
BioServe Purchases Genomics Collaborative.....II-30
1$100
   Sigma-Aldrich and Epigentek Signs Licensing Agreement.....II-31
Constellation Pharmaceuticals and BioTrove Enter into R&D Collaboration.....II-31
1$100
   Salk Institute Researchers Present Full Epigenome Map.....II-32
Baylor College of Medicine Recognizes Epigenetic Affects on Obesity.....II-32
Prenatal Starvation Could Cause Epigenetic Modifications.....II-32
John Hopkins Scientists Reveal Epigenetic Modifications Take Place Over
  Lifetime.....II-32
Advances in Epigentic Regulation Focuses on Breast Cancer.....II-32
1$100
   Celgene Corporation (US).....II-33
CellCentric Ltd. (UK).....II-33
Epigenomics AG (Germany).....II-33
Epigentek Group, Inc. (US).....II-33
1$100
   Genpathway, Inc. (US).....II-34
Merck & Co., Inc. (US).....II-34
MGI Pharma, Inc. (US).....II-34
Millipore Corporation (US).....II-34
1$100
   OncoMethylome Sciences S.A (Belgium).....II-35
Orion Genomics (US).....II-35
1$100
   Table 1: World Recent Past, Current & Future Analysis for Epigenetics by Application Area - Drug Discovery, Diagnostics and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-361$350
   Table 2: World 10-Year Perspective for Epigenetics by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery, Diagnostics, and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart).....II-371$350
  
Total Companies Profiled: 39 (including Divisions/Subsidiaries - 42)

Region/Country Players

The United States 25 Canada 1 Japan 2 Europe 11 Germany 3 The United Kingdom 4 Rest of Europe 4 Asia-Pacific (Excluding Japan) 3
Click here to request a full table of contents and more details on this project.